^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
IBI-323
i
Other names: IBI-323, IBI323
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Innovent Biologics
Drug class:
PD-L1 inhibitor, LAG-3 inhibitor
Related drugs:
4ms
Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC (clinicaltrials.gov)
P2, N=70, Recruiting, Hunan Province Tumor Hospital | Not yet recruiting --> Recruiting | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
Enrollment open • Trial completion date • Trial primary completion date
|
ALK (Anaplastic lymphoma kinase)
|
ALK rearrangement
|
Avastin (bevacizumab) • Alecensa (alectinib) • IBI-323
9ms
Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC (clinicaltrials.gov)
P2, N=80, Not yet recruiting, Hunan Province Tumor Hospital | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date
|
ALK (Anaplastic lymphoma kinase)
|
ALK rearrangement
|
Avastin (bevacizumab) • Alecensa (alectinib) • IBI-323
Share via
